Although ER- and/or PR-positive DCIS patients are mandated to receive endocrine therapy by NCCN guidelines [28], only 69.6% of HR-positive patients received tamoxifen, toremifene, or aromatase inhibitor in this study. This evidence concerns the gene ESR1 and ductal breast carcinoma in situ.